Active	Status	Sponsor type	Region	Phase	Filter
8 Active 1 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhao, Lin
DCAP, NCT04868565: Target Weaning Oxygen to Determine Cafffeine Duration for AOP	Completed	4	310	RoW	Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]	Children's Hospital of Chongqing Medical University	Apnea of Prematurity, Caffeine, Weaning Oxygen, Medicine Regimen	10/23	10/23
EVOLO-CTO, NCT05623995: Effect of Evolocumab on Chronic Total Occlusions	Recruiting	4	200	RoW	PCSK9 inhibitor, Evolocumab, Statin, Hydroxymethylglutaryl-Coenzyme A Reductase inhibitor	Lin Zhao	In-stent Restenosis, Major Adverse Cardiovascular Events	12/24	12/25
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer	Recruiting	3	560	RoW	Irinotecan Hydrochloride Injection, HX008, Placebo	Taizhou Hanzhong biomedical co. LTD	Stomach Cancer	08/23	08/23
NCT03322969: Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy	Recruiting	2	60	RoW	Paclitaxel/DDP, Group A, XELOX/SOX, Group B	Peking Union Medical College Hospital	Locally Advanced Gastric Cancer	08/22	08/23
NCT05170542: The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.	Recruiting	2	42	RoW	Camrelizumab+S-1	Peking Union Medical College Hospital	Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC	12/25	01/26
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors	Recruiting	1/2	320	RoW	TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab	Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb	Advanced Cancer	02/25	05/25
FACT, NCT06655922: FAPI Imaging Assessment of Chronic Total Occlusion	Recruiting	N/A	167	RoW	FAPI Imaging	Lin Zhao, Affiliated Beijing Chaoyang Hospital of Capital Medical University	Chronic Total Occlusion (CTO)	08/26	08/26
CTO-CMR, NCT05614180: Chronic Total Occlusive Lesions CMR Study	Recruiting	N/A	400	RoW	Percutaneous coronary intervention	Lin Zhao	Chronic Total Occlusion, Image, Revascularization	12/24	12/25